Altrova Health (ATVHF) will host a live investor question-and-answer session to discuss its first U.S. sale of O-Spray. The session is scheduled for October 20, 2026, at 10:00 a.m. ET. Management will discuss the sale of 2,000 units, announced on October 19, and respond to general shareholder and investor inquiries. Participants can submit questions during the session.
Altrova Health (ATVHF) announced its first U.S. sale of 2,000 O-Spray units to a distributor of peptide products.
The sale was made under an October 17, 2026 sales agreement with a purchaser whose network includes healthcare practitioners and retail channels. O-Spray is a needle-free oral spray administered under the tongue. Altrova is building distributor relationships in the U.S. and internationally and expanding its peptide-based product pipeline for men's, women's and pet health. The company believes broader peptide access could increase demand for needle-free administration formats.
Altrova Health (ATVHF) will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, at the Sheraton Centre Toronto Hotel. CEO Geoff Benic is scheduled to present on the company’s recent milestones and future growth strategy to an audience of investors, family offices, institutional investors, capital markets professionals and service providers.
The summit features company presentations, networking sessions and curated 1-on-1 meetings connecting investors with selected issuers, as well as keynotes and panel discussions on industry developments. Altrova Health describes itself as a Canadian public company building a portfolio of health solutions, including exclusive Canadian distribution rights for the NIRLIGHT drug analysis device, the O-Spray product line and rapid detection strips through subsidiary Drug Lab 118.
Altrova Health (OTCQB: ATVHF) reported Q3 Fiscal 2026 results for the nine months ended June 30, 2026, with revenue rising to $112,000 from $15,551 a year earlier, driven by commercialization of its NIRLAB distribution channels and broader recurring sales activity.
Gross profit increased to $62,488, while gross margin declined to 55.8% from 62.4%, reflecting a shift from early-stage transactions to more diversified commercial sales. Net and comprehensive loss widened to $2,351,996 from $1,098,177, with over 60% of the increase attributed to a non-cash $330,640 write-off from terminating an exclusive license and a $463,785 rise in non-cash share-based compensation.
According to Altrova Health, the company achieved its first meaningful product revenue, expanded its distribution network with NIRLAB device sales and Indigenous and First Nations partnerships, completed a rebrand and cross-border uplisting (CSE: ROVA, OTCQB: ATVHF), and reduced general and administrative, investor relations and professional fees.
Altrova Health (OTCQB: ATVHF, CSE: ROVA) announced a corporate update covering trading, commercialization, product sales, and governance. Its common shares began trading on the OTCQB under the new symbol ATVHF on July 17, 2026, replacing SSPLF, with no change to share structure or CUSIP.
The company reported ongoing commercial rollout efforts for its O-Spray product line and the sale of an additional NIRLAB NIRLIGHT drug analysis device to a First Nation community. Altrova is relaunching its rapid detection strip portfolio via subsidiary Drug Lab 118 under the Altrova brand, focusing on U.S. and Canadian distribution. It is also onboarding Castlewood Capital Corporation and Blaise Yerly as new advisors, and clarified that former chairman Raf Souccar has no current role with the company.